Novel Inhibitors of the Androgen Receptor for the Treatment of Castration Resistant Prostate Cancer (Crpc)

**UA ID** Technology #ua14-091

**Invention:**

The invention is a new class of heterocyclic small-molecules designed to antagonize the androgen receptor. These molecules have promising biological activity in a prostate specific cell line.

**Background**

The primary method for treating early stage prostate cancer is via androgen deprivation therapy because prostate cancer needs androgen in order to fuel growth. However, this form of therapy is sub-par because the tumor can develop a method to circumvent the need for large quantities of androgen by simply adding more androgen receptors. A new method of treatment is needed in order to better treat prostate cancer.

**Advantages:**

- Targets receptor and not the hormone itself
- Several variation of molecules, giving a wide variety of mechanisms for the antagonizing effect
- Effects are targeted, leading to predictable and preventable side effects

**Applications:**

- Treatment of prostate cancer
- Slowing the progression of prostate cancer
- Combination therapy to be utilized with other prostate cancer therapies
Patent Information: Provisional Patent Application Filed

Licensing Manager:
Kaitlyn Norman-Powers
KaitlynN@tla.arizona.edu
520-621-9907
Reference Tech-ID: UA14-091

Inventors
Vijay Gokhale
Senior Research Scientist, BIO5

Yeng Jeng Shaw
Research Associate, Pharmacology & Toxicology

Christopher Hulme
Professor